Author Archive for: TG

Alzheimer’s disease means memory loss for those affected. Beyond this, however, it is above all relatives and care staff who are impacted when the loss of cognitive abilities is accompanied by symptoms such as agitation, aggression, anxiety and depression, making home care impossible. This aspect of the disease is now gaining greater visibility through a major second financing round from EQT LifeScience, Gimv and Andera Partners with Exciva from Heidelberg.

Last week, Genmab and AbbVie hit a setback with epcoritamab, after the bispecific T-cell-engaging antibody failed to deliver a survival benefit in a phase 3 study in relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The EPCORE DLBCL-1 trial missed its primary endpoint of overall survival, the partners said on Friday. While epcoritamab did slow disease progression and performed better across several secondary measures, the survival miss overshadows the readout. 

The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have together compiled ten principles for good artificial intelligence (AI) practice in drug development.

The Novo Nordisk Foundation has committed up to DKK 5.5 billion (€736 million) to the BioInnovation Institute (BII), a Copenhagen-based hub for life science and deep tech entrepreneurship. The long-term funding, running from 2026 to 2035, aims to strengthen Denmark’s innovation capacity while helping Europe turn scientific excellence into companies, jobs and solutions.

Fresenius Kabi and TQ Therapeutics have entered into a strategic development agreement in cell and gene therapy. Fresenius Kabi receives an exclusive licence to develop, manufacture and distribute products incorporating TQ’s cell selection technology. The aim is to enable more scalable, efficient cell therapy production and broader, more cost-effective patient access.